Ticker

Preclinical data demonstrate deep and durable tumor regressions with lead product candidate ERNA-101 in combination with PD-1 Blockade in ovarian cancer

Ernexa Therapeutics Inc. (NASDAQ: ERNA - Get Free Report) saw a significant growth in short interest in the month of February. As of February 27th, there was short interest totaling 247,054 shares, a growth of 136.9% from the February 12th total of 104,299 shares. Currently, 3.3% of the company's shares are sold short. Based on an

Ernexa Therapeutics (NASDAQ: ERNA - Get Free Report) and Aditxt (NASDAQ: ADTX - Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, analyst recommendations, earnings, valuation and profitability. Insider and Institutional Ownership 70.6% of Ernexa Therapeutics

Ernexa Therapeutics Inc. (NASDAQ: ERNA - Get Free Report) shares were down 11.4% during trading on Monday. The company traded as low as $0.2703 and last traded at $0.2703. Approximately 1,070,042 shares were traded during trading, a decline of 65% from the average daily volume of 3,040,254 shares. The stock had previously closed at $0.3051.

Live video webcast with Sanjeev Luther, President and Chief Executive Officer of Ernexa Therapeutics, on Wednesday, February 25th at 4:00 PM ET